Abstract
There is growing evidence that adiponectin, an adipocytokine with anti-inflammatory and antiathero-genic properties, is involved in the development of atherosclerosis. The aim of the present study was to examine whether serum levels of adiponectin were associated with symptomatic atherosclerotic peripheral arterial disease (PAD). Serum concentrations of adiponectin were measured in 433 patients with symptomatic PAD and 433 controls from the Linz Peripheral Arterial Disease (LIPAD) study. Cases and controls were matched for age, sex and diabetes mellitus. The median serum level of adiponectin was significantly lower in PAD patients than in control subjects (9.5 vs. 10.8mg/L; p=0.014). After adjustment for several possible confounding variables using multivariable logistic regression, odds ratios for symptomatic PAD were 0.95 (95% CI, 0.64–1.42; p=0.080) and 0.59 (95% CI, 0.36–0.97; p=0.037) in the second and third tertiles for adiponectin serum concentrations, respectively, compared with the first tertile. Low serum levels of adiponectin were associated with the presence of symptomatic atherosclerotic PAD, independent of traditional and non-traditional risk factors, suggesting that hypoadiponectinemia may be a marker for systemic atherosclerotic disease.
Clin Chem Lab Med 2006;44:830–3.
References
1. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005; 6:7–14.10.1016/j.atherosclerosissup.2005.02.003Search in Google Scholar
2. Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta 2004; 344:1–12.10.1016/j.cccn.2004.02.020Search in Google Scholar
3. Iwashima Y, Horio T, Suzuki Y, Kihara S, Rakugi H, Kangawa K, et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 2005 Nov 28; Epub ahead of print (doi:10.1016/j.atherosclerosis.2005.10.039).Search in Google Scholar
4. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al. Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003; 163:884–92.10.1001/archinte.163.8.884Search in Google Scholar
5. Mueller T, Marschon R, Dieplinger B, Haidinger D, Gegenhuber A, Poelz W, et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study. J Vasc Surg 2005; 41:808–15.10.1016/j.jvs.2005.01.039Search in Google Scholar
6. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26:517–38.10.1016/S0741-5214(97)70045-4Search in Google Scholar
7. Clinical and Laboratory Standards Institute. Evaluation of precision performance of clinical chemistry devices; approved guideline. NCCLS document EP5-A. Wayne, PA: CLSI, 1999.Search in Google Scholar
8. Iwashima Y, Katsuya T, Ishikawa K, Kida I, Ohishi M, Horio T, et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension 2005; 45:1094–100.10.1161/01.HYP.0000169444.05588.4cSearch in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
